Literature DB >> 10225218

Functional recovery after central infusion of alpha-melanocyte-stimulating hormone in rats with spinal cord contusion injury.

A J Lankhorst1, S E Duis, M P ter Laak, E A Joosten, F P Hamers, W H Gispen.   

Abstract

Melanocortins, peptides related to alpha-melanocortin-stimulating hormone (alpha MSH) and adrenocorticotropic hormone (ACTH), are known to improve axonal regeneration following peripheral nerve injury and stimulate neurite outgrowth from central nervous system (CNS) neurons both in vitro and in vivo. The neurite outgrowth promoting capacity of alpha MSH has prompted us to investigate the effects of intrathecal application of alpha MSH on functional and electrophysiological recovery in a well-characterized model of spinal cord contusion injury. Different doses of alpha MSH were applied via osmotic minipumps into the cisterna magna for 10 days, thereby delivering the peptide directly into the CNS. Functional recovery was monitored during 8 postoperative weeks by means of the Basso, Beattie, and Bresnahan locomotor rating scale, and the thoracolumbar height test. At the end of the study, electrophysiological analysis of rubrospinal motor evoked potentials as performed. Our data showed that application of 3.75 micrograms/kg/h alpha MSH resulted in a marked functional recovery, accompanied by a decrease in the latency of the rMEP. This study demonstrates that intrathecal application of alpha MSH results in functional recovery after spinal cord contusion injury. These findings may initiate new treatment strategies and/or the use of melanocortins in human spinal cord injury.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225218     DOI: 10.1089/neu.1999.16.323

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  7 in total

1.  Involvement of ERK2 in traumatic spinal cord injury.

Authors:  Chen-Guang Yu; Robert P Yezierski; Aashish Joshi; Kashif Raza; Yanzhang Li; James W Geddes
Journal:  J Neurochem       Date:  2010-01-12       Impact factor: 5.372

2.  Neuroprotective effects of melanocortins in experimental spinal cord injury. An experimental study in the rat using topical application of compounds with varying affinity to melanocortin receptors.

Authors:  H S Sharma; A Skottner; T Lundstedt; M Flärdh; L Wiklund
Journal:  J Neural Transm (Vienna)       Date:  2006-04       Impact factor: 3.575

3.  Melanocortins applied intravitreally delay retinal dystrophy in Royal College of Surgeons rats.

Authors:  Nava Naveh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-30       Impact factor: 3.117

4.  RGMa inhibition with human monoclonal antibodies promotes regeneration, plasticity and repair, and attenuates neuropathic pain after spinal cord injury.

Authors:  Andrea J Mothe; Nardos G Tassew; Alirezha P Shabanzadeh; Romeo Penheiro; Robin J Vigouroux; Lili Huang; Christine Grinnell; Yi-Fang Cui; Emma Fung; Philippe P Monnier; Bernhard K Mueller; Charles H Tator
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

5.  Human induced pluripotent stem cells integrate, create synapses and extend long axons after spinal cord injury.

Authors:  Nicolas Stoflet Lavoie; Vincent Truong; Dane Malone; Thomas Pengo; Nandadevi Patil; James R Dutton; Ann M Parr
Journal:  J Cell Mol Med       Date:  2022-03-08       Impact factor: 5.310

6.  Pharmacological Suppression of CNS Scarring by Deferoxamine Reduces Lesion Volume and Increases Regeneration in an In Vitro Model for Astroglial-Fibrotic Scarring and in Rat Spinal Cord Injury In Vivo.

Authors:  Christina Francisca Vogelaar; Brigitte König; Stefanie Krafft; Veronica Estrada; Nicole Brazda; Brigida Ziegler; Andreas Faissner; Hans Werner Müller
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

7.  Activation of Melanocortin-4 Receptor Inhibits Both Neuroinflammation Induced by Early Exposure to Ethanol and Subsequent Voluntary Alcohol Intake in Adulthood in Animal Models: Is BDNF the Key Mediator?

Authors:  Osvaldo Flores-Bastías; Alfredo Adriasola-Carrasco; Eduardo Karahanian
Journal:  Front Cell Neurosci       Date:  2020-01-28       Impact factor: 5.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.